Evidence map›Paper›PMID 39706478›Full record

ArticleMolecular & cellular proteomics : MCP2025

CySP3-96 Enables Scalable, Streamlined, and Low-Cost Sample Preparation for Cysteine Chemoproteomic Applications.

Flowreen Shikwana, Beeta S Heydari, Samuel Ofori, Cindy Truong, Alexandra C Turmon, Joelle Darrouj, Lara Holoidovsky, Jeffrey L Gustafson, Keriann M Backus

Erratum issuedAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. A unified photosensitizer platform forbioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Flowreen ShikwanaBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California, USA; Department of Chemistry and Biochemistry, UCLA, Los Angeles, California, USA.
Beeta S HeydariDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, California, USA.
Samuel OforiBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
Cindy TruongDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, California, USA.
Alexandra C TurmonBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California, USA; Department of Chemistry and Biochemistry, UCLA, Los Angeles, California, USA.
Joelle DarroujDepartment of Chemistry and Biochemistry, UCLA, Los Angeles, California, USA.
Lara HoloidovskyBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.
Jeffrey L GustafsonDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, California, USA; Department of Chemistry, Stony Brook University, Stony Brook, New York, USA.
Keriann M BackusBiological Chemistry Department, David Geffen School of Medicine, UCLA, Los Angeles, California, USA; Department of Chemistry and Biochemistry, UCLA, Los Angeles, California, USA; Molecular Biology Institute, UCLA, Los Angeles, California, USA; DOE Institute for Genomics and Proteomics, UCLA, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA; Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, UCLA, Los Angeles, California, USA. Electronic address: kbackus@mednet.ucla.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
MIRA: Atropisomerism as an inspiration for drug discovery and new chemistryR35GM124637 · NIGMS · STATE UNIVERSITY NEW YORK STONY BROOK · PI Jeffrey Louis Gustafson · 2017 to 2026
$3.8M
NCI NIH HHS P50 CA211015NIGMS NIH HHS R35 GM124637
6 · The paper itself

Abstract

Cysteine chemoproteomic screening platforms are widely utilized for chemical probe and drug discovery campaigns. Chemoproteomic compound screens, which use a mass spectrometry-based proteomic readout, can interrogate the structure activity relationship for thousands of proteins in parallel across the proteome. The versatility of chemoproteomic screens has been demonstrated across electrophilic, nucleophilic, and reversible classes of molecules. However, a key bottleneck that remains for these approaches is the low throughput nature of the most established sample preparation workflows, which rely on many time-intensive and often error prone steps. Addressing these challenges, here we establish a novel workflow, termed CySP3-96, that pairs single-pot, solid-phase-enhanced, sample preparation (SP3) with a customized 96-well sample cleanup workflow to achieve streamlined multiplexed sample preparation. Our CySP3-96 method addresses prior volume limitations of SP3, which allows for seamless 96-well chemoproteomic sample preparation, including for large input amounts that are incompatible with prior methods. By deploying CySP3-96 to screen a focused set of 16 cysteine-reactive compounds, we identify 2633 total ligandable cysteines, including 21 not captured in CysDB. Chemoproteomic analysis of a pair of atropisomeric electrophilic kinase inhibitors reveals striking stereoselective cysteine ligandability for 67 targets across the proteome. When paired with our innovative budget friendly magnetic resin, CySP3-96 represents a versatile, low cost, and highly reproducible screening platform with widespread applications spanning all types of chemoproteomic studies.

Indexed as

CysteineProteomicsHumansProteomeWorkflowCysteineProteome96-wellatropisomerchemoproteomiccovalentcysteineSP3

Identifiers

PMID39706478
PMCPMC12529508

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.